GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Chongqing Genrix Biopharmaceutical Co Ltd (SHSE:688443) » Definitions » Market Cap

Chongqing Genrix Biopharmaceutical Co (SHSE:688443) Market Cap : ¥10,219.37 Mil (As of Dec. 13, 2024)


View and export this data going back to 2023. Start your Free Trial

What is Chongqing Genrix Biopharmaceutical Co Market Cap?

Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Chongqing Genrix Biopharmaceutical Co's share price for the quarter that ended in Sep. 2024 was ¥30.4. Chongqing Genrix Biopharmaceutical Co's Shares Outstanding (EOP) for the quarter that ended in Sep. 2024 was 366.68 Mil. Therefore, Chongqing Genrix Biopharmaceutical Co's market cap for the quarter that ended in Sep. 2024 was ¥11,147.07 Mil.

Chongqing Genrix Biopharmaceutical Co's quarterly market cap declined from Mar. 2024 (¥14,766.20 Mil) to Jun. 2024 (¥10,905.06 Mil) but then increased from Jun. 2024 (¥10,905.06 Mil) to Sep. 2024 (¥11,147.07 Mil).

Chongqing Genrix Biopharmaceutical Co's annual market cap stayed the same from Dec. 2021 (¥0.00 Mil) to Dec. 2022 (¥0.00 Mil) but then increased from Dec. 2022 (¥0.00 Mil) to Dec. 2023 (¥14,648.87 Mil).

Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Chongqing Genrix Biopharmaceutical Co's Enterprise Value for Today is ¥8,548.59 Mil.


Chongqing Genrix Biopharmaceutical Co Market Cap Historical Data

The historical data trend for Chongqing Genrix Biopharmaceutical Co's Market Cap can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Genrix Biopharmaceutical Co Market Cap Chart

Chongqing Genrix Biopharmaceutical Co Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Market Cap
- - - - 14,648.87

Chongqing Genrix Biopharmaceutical Co Quarterly Data
Dec19 Dec20 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Market Cap Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11,308.41 14,648.87 14,766.20 10,905.06 11,147.07

Competitive Comparison of Chongqing Genrix Biopharmaceutical Co's Market Cap

For the Biotechnology subindustry, Chongqing Genrix Biopharmaceutical Co's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Chongqing Genrix Biopharmaceutical Co's Market Cap Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Chongqing Genrix Biopharmaceutical Co's Market Cap distribution charts can be found below:

* The bar in red indicates where Chongqing Genrix Biopharmaceutical Co's Market Cap falls into.



Chongqing Genrix Biopharmaceutical Co Market Cap Calculation

Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.

Chongqing Genrix Biopharmaceutical Co's Market Cap for the fiscal year that ended in Dec. 2023 is calculated as

Market Cap (A: Dec. 2023 )=Share Price (A: Dec. 2023 )*Shares Outstanding (EOP) (A: Dec. 2023 )
=¥39.95*366.68
=¥14,648.87

Chongqing Genrix Biopharmaceutical Co's Market Cap for the quarter that ended in Sep. 2024 is calculated as

Market Cap (Q: Sep. 2024 )=Share Price (Q: Sep. 2024 )*Shares Outstanding (EOP) (Q: Sep. 2024 )
=¥30.4*366.68
=¥11,147.07

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Chongqing Genrix Biopharmaceutical Co  (SHSE:688443) Market Cap Explanation

Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the company’s debt. The real price you pay is the Enterprise Value.

Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.


Chongqing Genrix Biopharmaceutical Co Market Cap Related Terms

Thank you for viewing the detailed overview of Chongqing Genrix Biopharmaceutical Co's Market Cap provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Genrix Biopharmaceutical Co Business Description

Traded in Other Exchanges
N/A
Address
No. 699, Maliu Avenue, Area A, Building 2, International Bio City, Banan, Chongqing, CHN, 401338
Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.
Executives
Jiang Ren Sheng Director

Chongqing Genrix Biopharmaceutical Co Headlines

No Headlines